Table 2.

Multivariate analysis of factors associated with outcomes of patients with Ph positive ALL who underwent allo-SCT (n = 202).

Covariate	Univariate analysis			Multivariate analysis
	HR	95% CI	P-value	HR	95% CI	P-value
Relapse
Disease status*	2.953	1.500–5.815	0.002	4.079	1.821–9.137	0.001
Pre-transplantation MRD (positive vs. negative)	2.584	1.206–5.539	0.015
Donor-recipient sex-matched graft
Female-male	0.928	0.232–3.710	0.916	0.518	0.112–2.392	0.399
Female-female	3.817	1.196–12.181	0.024	3.248	1.006–10.484	0.049
Male-male	1.655	0.509–5.378	0.402	1.464	0.448–4.789	0.528
Male-female		1			1
Transplant–related mortality
Platelet engraftment (yes vs. no)	0.047	0.020–0.107	<0.001	0.047	0.020–0.107	<0.001
Leukemia-free survival
Donor-recipient sex-matched graft
Female-male	0.774	0.306–1.962	0.590	1.344	0.499–3.568	0.566
Female-female	2.363	1.072–5.209	0.033	3.166	1.414–7.086	0.005
Male-male	1.505	0.708–3.196	0.288	2.426	1.088–5.408	0.030
Male-female		1		1
Platelet engraftment (yes vs. no)	0.067	0.033–0.133	<0.001	0.054	0.025–0.115	<0.001
Overall survival
Disease status	1.956	0.980–3.905	0.057
Donor-recipient sex-matched graft
Female-male	0.492	0.168–1.439	0.195	0.898	0.290–2.780	0.851
Female-female	1.823	0.799–4.158	0.154	2.471	1.067–5.723	0.035
Male-male	1.352	0.629–2.909	0.440	2.290	1.006–5.215	0.048
Male-female		1			1
Platelet engraftment (yes vs. no)	0.059	0.029–0.119	<0.001	0.050	0.023–0.110	<0.001

allo-SCT, allogeneic stem cell transplantation; MRD, measurable residual disease; HR, hazard ratio; CI, confidence interval.

^*All variables were first included in the univariate analysis, including sex, age, donor-recipient sex-matched grafts, donor-recipient relationship, ABO matched graft, pre-transplantation MRD status, disease status and hematopoietic engraftments; only variables with P < 0.1 were included in the Cox proportional hazards model with time-dependent variables.